A new market research report from Future Market Insights on the Atopic Dermatitis Treatment Market includes 2014-2021 Global Industry Analysis and 2022-2029 Opportunity Assessment. The report studies the Atopic Dermatitis Treatment market and provides key insights for the forecast period 2022-2029. According to the findings of the report, the global atopic dermatitis treatment market is expected to witness significant growth over the forecast period, driven by increasing prevalence, promising pipeline molecules, higher treatment compliance , increased access to treatment drugs in developing countries, favorable reimbursement policies, increasing government support for research and development and advancing technology.
The Global Atopic Dermatitis Treatment Market was rated at US$5.2 billion in 2021 and is expected to reach US$7.6 billion by 2029, finds Future Market Insights (IMF) in a recent market study.
Corticosteroids remain the drug of choice
Corticosteroids are considered the first choice of treatment for inflammation and pain relief. These drugs are known to have effects, for example, decreased tingling, allergic reactions, swelling and redness.
Request a sample report for complete information on
About 30 corticosteroid compounds have been approved for the treatment of atopic dermatitis, of which “hydrocortisone” is believed to be the first. Furthermore, the growing innovations have resulted in the advent of non-corticosteroid topical immunomodulators and target drugs, for example, immunomodulators such as pimecrolimus and tacrolimus, which in turn, are likely to fuel the growth of the treatment market. atopic dermatitis. Additionally, topical corticosteroids should play an important role in the treatment of atopic dermatitis..
|Data points||Market overview|
|Market value 2021||$5.2 billion|
|Market value 2029||$7.6 billion|
|Share of top 5 countries||52.1%|
|Key players||Major Players of Atopic Dermatitis Treatment Market are Sanofi SA, Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Valeant Pharmaceutical International Inc. .|
North America will provide high sales opportunities
Growth prospects for the atopic dermatitis treatment market are expected to be high in North America during the forecast period 2022-2029. Factors such as greater awareness of treatment among the patient population in the United States and Canada, early adoption of new prescriptions, advanced healthcare infrastructure, better and supportive reimbursement policies, and the Increased commercial associations of pharmaceutical organizations with contract research organizations in developing markets will continue to propel the growth of the atopic dermatitis treatment market. Despite the fact that the United States and Canada face heavy investments in health infrastructure as well as per capita expenditures, there is an increasing number of campaigns organized each year by specific institutions, for example, the national eczema associations, the PAN Foundation and pharmaceutical organizations, which are believed to work to the benefit of several market vendors.
For any questions related to the report, ask an [email protected] https://www.futuremarketinsights.com/ask-question/rep-gb-3097
Hospital pharmacies – The key distribution channel for the treatment of atopic dermatitis
Sales of drugs for the treatment of atopic dermatitis by hospital pharmacies will continue to represent a relatively high share of the market, as they can stock a wide range of prescription drugs, including progressively specific and experimental drugs. Hospital pharmacies can supply a huge amount of medication every day, which is distributed to wards and intensive care units according to the patient’s prescription schedule.
Topical Medication Administration – A Preferred Mode
The topical mode of administration remains highly preferred among the group of patients with atopic dermatitis. The advent of non-corticosteroid topical immunomodulators is the main growth factor in the demand for the treatment of atopic dermatitis. As topical administration grows in importance, major corticosteroids are formulated in topical form, in addition to their advantages over the oral dosage form.
Atopic Dermatitis Treatment Market: Vendor Insights
The report sheds light on some of the major market players, who have emerged as leaders in the global atopic dermatitis treatment market. Some of the examples of key players in the global atopic dermatitis treatment market are Sanofi SA, Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals Inc., Astellas Pharma, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals and Valeant Pharmaceuticals International, Inc.
We offer bespoke solutions to meet your needs, request customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-3097
Discover IMF’s extensive ongoing healthcare coverage
Canine Atopic Dermatitis Treatment Market – The Global Canine Atopic Dermatitis Treatment Market is estimated to exceed US$2.37 billion by the end of 2029. Increasing emphasis on the development of new therapies such as monoclonal antibodies for the treatment of atopic dermatitis in dogs and cats is expected to drive the market growth.
Feline Atopic Dermatitis Treatment Market – Feline atopic dermatitis is the inflammation of the skin seen in cats. Feline atopic dermatitis is often triggered by causative allergens that are either inhaled or come into contact with the skin, resulting in inflammation of the skin.
Traumatic Brain Injury Treatment Market – Each year, Traumatic Brain Injury (TBI) contributes to a significant number of cases worldwide. TBI can be defined as injury to the brain resulting from external trauma resulting in damage to brain cells and blood vessels.
Allergy Treatment Market – An allergy is an increased sensitivity of the immune system. Allergy occurs when an inherently harmless foreign substance reacts with the immune system. These foreign substances are called allergens.
Substance Use Disorder Treatment Market – According to the World Health Organization (WHO), the leading cause of disability worldwide is not physical illness, but a serious mood disorder called depression. Around 350 million people worldwide suffer from depression and only around 50% of these people will ever receive treatment.
About Future Market Insights (IMF)
Future Market Insights (FMI) is a leading provider of market information and advisory services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, USA and India. FMI’s latest market research reports and industry analysis help businesses meet challenges and make critical decisions with confidence and clarity amidst fierce competition. Our custom and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of analysts led by FMI experts continuously monitor emerging trends and events across a wide range of industries to ensure our clients are prepared for the changing needs of their consumers.
future market outlook,
1602-6 Jumeirah Bay Tower X2,
Parcel number: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For sales inquiries: [email protected]
For media inquiries: [email protected]